S Y Park1, J S Son, I H Oh, J M Choi, M S Lee. 1. Division of Infectious Diseases, Department of Internal Medicine, School of Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul, 130-701, Korea.
Abstract
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen not only in nosocomial infections, but also in community-associated infections. The aim of this study was to evaluate the impacts of methicillin resistance on mortality, length of hospitalization, and hospital costs via propensity score matching in S. aureus bacteremia. PATIENTS AND METHODS: A propensity-matched case-control study was conducted in a tertiary hospital in Korea from 2003 to 2008. RESULTS: A total of 266 patients who had clinically significant S. aureus bloodstream infections were investigated. Fifty-three propensity-matched case-control pairs with MRSA bacteremia were likely to have stayed in the hospital longer before developing bacteremia (mean 25.0 vs. 6.1 days; P = 0.01). However, after developing bacteremia, the differences in the mean duration of hospital stay was not significant (mean 35.0 vs. 28.7 days; P = 0.33). Similar numbers of MRSA and methicillin-susceptible S. aureus (MSSA) patients died (P = 0.48). The mean total hospital costs after S. aureus bacteremia increased more for MRSA patients compared to MSSA patients. However, this difference was not statistically significant ($9,369.6 vs. $8,355.8; P = 0.62). CONCLUSIONS: This study indicates that MRSA bacteremia is not associated with higher risks of mortality or hospital costs. It is, however, associated with a substantial increase in the length of hospital stay as compared to MSSA bacteremia. This information may help clinicians and policymakers derive methods to control the impacts of MRSA infection.
BACKGROUND:Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen not only in nosocomial infections, but also in community-associated infections. The aim of this study was to evaluate the impacts of methicillin resistance on mortality, length of hospitalization, and hospital costs via propensity score matching in S. aureus bacteremia. PATIENTS AND METHODS: A propensity-matched case-control study was conducted in a tertiary hospital in Korea from 2003 to 2008. RESULTS: A total of 266 patients who had clinically significant S. aureus bloodstream infections were investigated. Fifty-three propensity-matched case-control pairs with MRSA bacteremia were likely to have stayed in the hospital longer before developing bacteremia (mean 25.0 vs. 6.1 days; P = 0.01). However, after developing bacteremia, the differences in the mean duration of hospital stay was not significant (mean 35.0 vs. 28.7 days; P = 0.33). Similar numbers of MRSA and methicillin-susceptible S. aureus (MSSA) patients died (P = 0.48). The mean total hospital costs after S. aureus bacteremia increased more for MRSA patients compared to MSSA patients. However, this difference was not statistically significant ($9,369.6 vs. $8,355.8; P = 0.62). CONCLUSIONS: This study indicates that MRSA bacteremia is not associated with higher risks of mortality or hospital costs. It is, however, associated with a substantial increase in the length of hospital stay as compared to MSSA bacteremia. This information may help clinicians and policymakers derive methods to control the impacts of MRSA infection.
Authors: Leonard A Mermel; Michael Allon; Emilio Bouza; Donald E Craven; Patricia Flynn; Naomi P O'Grady; Issam I Raad; Bart J A Rijnders; Robert J Sherertz; David K Warren Journal: Clin Infect Dis Date: 2009-07-01 Impact factor: 9.079
Authors: B C Herold; L C Immergluck; M C Maranan; D S Lauderdale; R E Gaskin; S Boyle-Vavra; C D Leitch; R S Daum Journal: JAMA Date: 1998-02-25 Impact factor: 56.272
Authors: S Hansen; F Schwab; A Asensio; H Carsauw; P Heczko; I Klavs; O Lyytikäinen; M Palomar; I Riesenfeld-Orn; A Savey; E Szilagyi; R Valinteliene; J Fabry; P Gastmeier Journal: Infection Date: 2010-03-16 Impact factor: 3.553
Authors: Shelby D Reed; Joëlle Y Friedman; John J Engemann; Robert I Griffiths; Kevin J Anstrom; Keith S Kaye; Martin E Stryjewski; Lynda A Szczech; L Barth Reller; G Ralph Corey; Kevin A Schulman; Vance G Fowler Journal: Infect Control Hosp Epidemiol Date: 2005-02 Impact factor: 3.254
Authors: R Monina Klevens; Melissa A Morrison; Joelle Nadle; Susan Petit; Ken Gershman; Susan Ray; Lee H Harrison; Ruth Lynfield; Ghinwa Dumyati; John M Townes; Allen S Craig; Elizabeth R Zell; Gregory E Fosheim; Linda K McDougal; Roberta B Carey; Scott K Fridkin Journal: JAMA Date: 2007-10-17 Impact factor: 56.272
Authors: Sebastian J van Hal; Slade O Jensen; Vikram L Vaska; Björn A Espedido; David L Paterson; Iain B Gosbell Journal: Clin Microbiol Rev Date: 2012-04 Impact factor: 26.132
Authors: A J Kaasch; S Rieg; J Kuetscher; H-R Brodt; T Widmann; M Herrmann; C Meyer; T Welte; P Kern; U Haars; S Reuter; I Hübner; R Strauss; B Sinha; F M Brunkhorst; M Hellmich; G Fätkenheuer; W V Kern; H Seifert Journal: Infection Date: 2013-03-29 Impact factor: 3.553
Authors: S-Y Park; Y P Chong; H J Park; K-H Park; S M Moon; J-Y Jeong; M-N Kim; S-H Kim; S-O Lee; S-H Choi; J H Woo; Y S Kim Journal: Infection Date: 2012-10-12 Impact factor: 3.553
Authors: Young Kyung Yoon; Dae Won Park; Jang Wook Sohn; Hyo Youl Kim; Yeon-Sook Kim; Chang-Seop Lee; Mi Suk Lee; Seong-Yeol Ryu; Hee-Chang Jang; Young Ju Choi; Cheol-In Kang; Hee Jung Choi; Seung Soon Lee; Shin Woo Kim; Sang Il Kim; Eu Suk Kim; Jeong Yeon Kim; Kyung Sook Yang; Kyong Ran Peck; Min Ja Kim Journal: Antimicrob Agents Chemother Date: 2013-10-28 Impact factor: 5.191
Authors: Marta Riu; Pietro Chiarello; Roser Terradas; Maria Sala; Enric Garcia-Alzorriz; Xavier Castells; Santiago Grau; Francesc Cots Journal: PLoS One Date: 2016-04-07 Impact factor: 3.240